pr400069f_si_004.pdf (83.28 kB)
Quantitative Analytical Method for Determining the Levels of Gastric Inhibitory Polypeptides GIP1–42 and GIP3–42 in Human Plasma Using LC–MS/MS/MS
journal contribution
posted on 2013-06-07, 00:00 authored by Atsushi Miyachi, Takayo Murase, Yuichiro Yamada, Takeshi Osonoi, Ken-ichi HaradaGastric inhibitory polypeptide (GIP),
an incretin, is an important
subject in endocrinology. Some LC–MS assays have been proposed;
however, their sensitivities are insufficient for the study of endogenous
human incretin. Here, we describe a nanoflow LC hybrid triple quadrupole/linear
ion trap MS assay for the simultaneous quantification of GIP1–42 and GIP3–42 from human plasma. We selected the
surrogate peptide to avoid oxidative modification, and the endoproteinase
Asp-N was selected for the proteolysis of GIP1–42 and GIP3–42. The phenylalanine residue at position
6 in both GIP1–42 and GIP3–42 was
substituted with 13C9,15N-labeled
phenylalanine, and these substituted GIPs were used as the internal
standards. This facilitated accurate and precise quantification because
large corrections are possible at all steps of sample pretreatment
and ionization efficiency. The lower limit of quantification was 1
pM for GIP1–42 and 10 pM for GIP3–42 by using 200 μL of plasma. Quantification of GIP1–42 and GIP3–42 in plasma from patients with type
2 diabetes was possible using this method, which included protein
precipitation, Asp-N proteolysis, solid-phase extraction, nanoflow
LC, and positive-ion multiple reaction monitoring cubed (MRM3) for GIP1–8, and MRM for GIP3–8 to achieve accurate, precise, and quantitative analysis that can
be validated to support large clinical trials.